Pathophysiologic bases for adjunctive therapies in the treatment and secondary prevention of acute myocardial infarction

被引：7

作者：

Gutstein, DE ^{[1
]}

Fuster, V ^{[1
]}

机构：

[1] Mt Sinai Med Ctr, Cardiovasc Inst, New York, NY 10029 USA

来源：

CLINICAL CARDIOLOGY | 1998年 / 21卷 / 03期

关键词：

myocardial infarction; adjunctive medical therapy; treatment; secondary prevention; pathophysiology;

D O I：

10.1002/clc.4960210305

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Postmyocardial infarction (MI) survival has been steadily improving. This improvement has been due, in part, to the actions of the adjunctive medical therapies for the treatment of MI. Aspirin, beta blockers, angiotensin-converting enzyme (ACE) inhibitors, and lipid-lowering agents have been shown to improve survival in the treatment and secondary prevention of MI. Nitrates have beneficial effects as well. These medications complement the reperfusion strategies through different mechanisms. Other adjunctive medical therapies, namely magnesium, antiarrhythmic agents, and calcium-channel blockers, have not been shown to improve mortality with routine post-MI use despite their theoretical benefits.

引用

页码：161 / 168

页数：8

共 91 条

[1] COLLABORATIVE OVERVIEW OF RANDOMIZED TRIALS OF ANTIPLATELET THERAPY .1. PREVENTION OF DEATH, MYOCARDIAL-INFARCTION, AND STROKE BY PROLONGED ANTIPLATELET THERAPY IN VARIOUS CATEGORIES OF PATIENTS [J].

ALTMAN, R ;

CARRERAS, L ;

DIAZ, R ;

FIGUEROA, E ;

PAOLASSO, E ;

PARODI, JC ;

CADE, JF ;

DONNAN, G ;

EADIE, MJ ;

GAVAGHAN, TP ;

OSULLIVAN, EF ;

PARKIN, D ;

RENNY, JTG ;

SILAGY, C ;

VINAZZER, H ;

ZEKERT, F ;

ADRIAENSEN, H ;

BERTRANDHARDY, JM ;

BRAN, M ;

DAVID, JL ;

DRICOT, J ;

LAVENNEPARDONGE, E ;

LIMET, R ;

LOWENTHAL, A ;

MORIAU, M ;

SCHAPIRA, S ;

SMETS, P ;

SYMOENS, J ;

VERHAEGHE, R ;

VERSTRAETE, M ;

ATALLAH, A ;

BARNETT, H ;

BATISTA, R ;

BLAKELY, J ;

CAIRNS, JA ;

COTE, R ;

CROUCH, J ;

EVANS, G ;

FINDLAY, JM ;

GENT, M ;

LANGLOIS, Y ;

LECLERC, J ;

NORRIS, J ;

PINEO, GF ;

POWERS, PJ ;

ROBERTS, R ;

SCHWARTZ, L ;

SICURELLA, J ;

TAYLOR, W ;

THEROUX, P .

BMJ-BRITISH MEDICAL JOURNAL, 1994, 308 (6921) :81-100

[2] THE EFFECT OF THE ANGIOTENSIN-CONVERTING ENZYME-INHIBITOR ZOFENOPRIL ON MORTALITY AND MORBIDITY AFTER ANTERIOR MYOCARDIAL-INFARCTION [J].

AMBROSIONI, E ;

BORGHI, C ;

MAGNANI, B .

NEW ENGLAND JOURNAL OF MEDICINE, 1995, 332 (02) :80-85

[3] NITRIC-OXIDE AND NITROVASODILATORS - SIMILARITIES, DIFFERENCES AND POTENTIAL INTERACTIONS [J].

ANDERSON, TJ ;

MEREDITH, IT ;

GANZ, P ;

SELWYN, AP ;

YEUNG, AC .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1994, 24 (02) :555-566

[4]

[Anonymous], 1989, NEW ENGL J MED, V321, P406

[5]

[Anonymous], 1990, LANCET, V336, P65

[6]

[Anonymous], 1988, LANCET, V1, P921

[7]

[Anonymous], 1988, LANCET, V2, P349

[8]

[Anonymous], 1989, NEW ENGL J MED, V320, P618

[9]

[Anonymous], 1986, Lancet, V2, P57

[10] Hirudin in acute myocardial infarction - Thrombolysis and thrombin inhibition in myocardial infarction (TIMI) 9B trial [J].

Antman, EM .

CIRCULATION, 1996, 94 (05) :911-921

← 1 2 3 4 5 6 7 8 9 10 →